Ni2o is developing a minimally invasive brain-computer interface (BCI) called KIWI to treat neurodegenerative diseases, starting with Parkinson's disease. This technology aims to reduce the complexity and risks associated with traditional deep brain stimulation treatments, providing a more accessible solution for the growing aging population.
Funding
$1.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Existing deep brain stimulation (DBS) treatments for neurodegenerative diseases like Parkinson's require invasive surgical procedures, including drilling holes into the skull and implanting devices, leading to potential complications and high costs. The aging global population faces an increasing risk of neurodegenerative diseases, creating a need for more accessible and less invasive treatment options.
Solution
Ni2o is developing KIWI, a minimally invasive brain-computer interface (BCI) designed to treat neurodegenerative diseases, initially targeting Parkinson's. KIWI aims to reduce the complexity and risks associated with traditional DBS by offering a less invasive implant procedure. The technology connects digital interfaces with organic brain functions to decode brain signals and provide therapeutic intervention. By focusing on minimally invasive techniques, Ni2o strives to lower treatment costs and improve accessibility for a broader patient population. The company's long-term vision includes expanding the application of its BCI technology to address other neurodegenerative conditions, such as Alzheimer's disease.
Target Audience
The primary target audience includes individuals suffering from neurodegenerative diseases, particularly Parkinson's disease, and healthcare providers seeking less invasive and more accessible treatment options.
Features
- Minimally invasive implant procedure compared to traditional deep brain stimulation.
- Brain-computer interface technology designed to decode brain signals.
- Initial focus on treating Parkinson's disease, with plans to expand to Alzheimer's.
- Aims to reduce the cost and complexity of neurodegenerative disease treatments.